Compare Cassava Sciences Inc (FLNA) vs Teladoc Health Inc (TDOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Teladoc Health Inc — how do they compare? Cassava Sciences Inc trades at $1.06 (market cap $53.14M), while Teladoc Health Inc trades at $9.54 (market cap $1.75B). The key difference: Teladoc Health Inc is far larger — about 32.9× Cassava Sciences Inc's market cap, and Teladoc Health Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | TDOC | |
|---|---|---|
Market Cap | $53.14M | $1.75B |
Sector | Health | Health |
52-Week High | $4.64 | $9.72 |
52-Week Low | $1.09 | $4.47 |
Enterprise Value | -$33.43M | $2.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
TDOC trades at $9.56, up 3.13% with bullish technical signals from moving averages. The company reported mixed Q1 2026 earnings, missing expectations with a -$0.36 EPS, but maintains strong revenue of $2.53B and a gross margin of 69.29%. Recent partnership expansions with Walmart highlight growth initiatives, though net losses persist at -$200.32M. Analyst consensus is mixed with 35.71% buy ratings but a price target below current levels at $8.75.
The outlook remains cautious due to ongoing net losses and negative cash flow trends, with net cash flow at -$517.24M in 2025. Key risks include competitive pressures and execution challenges, but cost-cutting and market expansion could support recovery. Investors should weigh the low P/S ratio of 0.69 against profitability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Teladoc Health Inc
Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →
